Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
- PMID: 32560014
- DOI: 10.1093/annonc/mdm584
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
Erratum for
-
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.Ann Oncol. 2007 Jul;18(7):1165-71. doi: 10.1093/annonc/mdm119. Epub 2007 Apr 17. Ann Oncol. 2007. PMID: 17442659 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources